Awarener easy mode Awarener analytic mode

Fundamental analysis: Aspira Womens Health Inc. (AWH)

Awarener score: 3.3

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Bottom), the business stability (Average) and growth (Excellent), and the company's inclination to return cash to the stockholders (Very poor).

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 7.5

  • Business has been growing at an excellent pace. It's been encouraging in relation to peer companies.
  • Aspira Womens Health Inc. business trend stability is run-of-the-mill. The higher the stability, the lower the risk. It looks somewhat worse than rivals.

Margins score: 2.5

  • AWH profit margins -on goods and services sold- are usually hardly sufficient. They stand worse than most rival companies.
  • Business profit on sales tends to be extremely poor. It's substantially worse when measured against competitors.
  • Profits on sales made -available to repay debt and purchase properties- are usually extremely poor. They remain in a very weak position compared to peers.
  • Earnings -before income taxes and interests on loans taken- tend to be extremely poor in relation to total revenues. They're still worse than most similar companies.
  • Profits -before income taxes- are usually extremely poor considering total sales, and remain substantially worse when measured against rivals.
  • Total net profit tends to be extremely poor when confronted to sales. Company stands substantially worse when measured against comparable firms.

Growth score: 1.0

  • Aspira Womens Health Inc. couldn't always profit -on goods and services sold- in the past years. It's been impressive in relation to competitors.
  • In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
  • In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
  • In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
  • In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
  • In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
  • The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 3.3

  • AWH had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
  • Research and development expenses consume quite a bit of revenues. It's below average when measured against competitors.
  • The company grows sparsely in relation to research and development efforts. It stands lacking compared to rival companies.

Profitability score: 1.0

  • Aspira Womens Health Inc. usually gets pauper returns on the resources it controls. It proves last-in-rank when measured against peer firms.
  • The company normally gets extremely poor proceeds -on the resources directly invested in the business-. They remain a disappointment compared to similar companies.
  • There's usually bottom profitability -in relation to owned resources-. It ranks last-in-rank when measured against competitors.
  • In the past, got pauper returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's last-in-rank when measured against comparable enterprises.

Usage of Funds score: 2.4

  • AWH on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands last-in-rank when measured against rival firms.
  • The company is usually replacing most of the property, plant, and equipment that gets old, and saving a little funds for something else, which is below average when measured against industry peers.
  • In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
  • The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
  • As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
  • The company has significantly enlarged the pool of investors in previous years, resulting in more mouths feeding on the pie of profits. It remains close to average when compared to peer enterprises.
  • Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
  • We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 6.8

  • Aspira Womens Health Inc. has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
  • The company has more than enough short-term resources to face short-term obligations. Liquidity concerns are non-significant. It turns to be a slight improvement compared to similar firms.
  • Roughly a tenth of resources controlled were provided for with financial debt. Creditors have minor claims on the company, and financial position is safe. It remains well ranked against rival firms.
  • Most resources controlled are already cash or short-term investments, which is best for liquidity. It looks top tier when measured against rivals.
  • For every dollar of short-term obligations, the company has more than enough dollars in cash and short-term receivables. It's a slight improvement compared to peer firms.
  • For every dollar of short-term obligations, the company has more than enough dollars in cash and equivalents, which is well ranked against similar enterprises.
  • Usually, sales are on a two-months credit. It still ranks encouraging in relation to peers.
  • Normally has approximately somewhat less than one month of sales worth in inventory. It comes up as excellent in relation to competitors.
  • On average, it takes higher than three months from the purchase to charging customers. It happens to be better than most peers.
  • On average pays suppliers approximately four months or higher after the purchase. It ranks great when measured against industry peers.
  • The company charges its customers long before it must pay its suppliers, so the more it sales, the more free funds it gets. It's impressive in relation to similar companies.
  • Has usually been losing money on the business, so net interest expenses must be paid by increasing borrowings, which is unsustainable in the long run. The situation is very risky for both creditors and shareholders, profitability must increase. It stands bottom tier against rival firms.
  • Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
  • Revenues are very good in relation to property, plant, and equipment required to operate. This metric is likely dependent on the industry the company operates in. Low property, plant, and equipment requirements allows the company to keep more money to reward stockholders in the long run. It looks excellent in relation to similar firms.
  • Resource exploitation is slightly low when yearly sales are considered, business volume should be increased. This metric is normally tied to the industry where the firm belongs. It's still mediocre against peer companies.

Valuation score: 2.4

  • Aspira Womens Health Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
  • Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains close to average when compared to peers.
  • In the past twelve months, the company consumed lots of funds. Either it reinvested heavily in the business or genuine fund generation might be struggling, which stands worse than most similar companies.
  • The company usually consumes plenty more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving outstanding business growth, genuine profitability may be brought into question. It's still substantially worse when measured against industry firms.
  • In the past twelve months, the company has largely enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among a lot more stockholders. It came up in a very weak position compared to peer ventures.
  • This company is a cash hoarder. It might be well poised to substantially increase stockholder payments, or to fund new business projects. It looks well ranked against similar enterprises.
  • Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
  • Comparing the current stock price with the past twelve-months revenues gives a very large relationship. The stock price might rely more on expectations and resources controlled than on anything else. It looks in a very weak position compared to rival firms.
  • The relation between the stock price and accounting book value is really high, which may be good or bad depending on context. Run again in analytic mode if you want to dig deeper. The company remains somewhat worse than peer firms.
  • In the past twelve months, the operating business lost plenty of money. It happens to be substantially worse when measured against industry peers.
  • In an alternate metric of bang for the buck, the company has usually shown an extremely low earnings power ability when measured against the current stock price and financial position. Profitability is significantly in dispute. It's still in a very weak position compared to peer companies.

Total score: 3.4


AWH logos

Company at a glance: Aspira Womens Health Inc. (AWH)

Sector, industry: Healthcare, Diagnostics & Research

Market Cap: 0.05 billions

Revenues TTM: 0.01 billions

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Awarener score: 3.3

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Bottom), the business stability (Average) and growth (Excellent), and the company's inclination to return cash to the stockholders (Very poor).